Cited by 1,475Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Health and Risk FactorsCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

Alexander, Charles M., Landsman, Pamela B., Teutsch, Steven M., Haffner, Steven M.·2003·Diabetes

DOI 10.2337/diabetes.52.5.1210

Open this paper in CoChat — free account

Abstract

Although the individual components of the metabolic syndrome are clearly associated with increased risk for coronary heart disease (CHD), we wanted to quantify the increased prevalence of CHD among people with metabolic syndrome. The Third National Health and Nutrition Examination Survey (NHANES III) was used to categorize adults over 50 years of age by presence of metabolic syndrome (National Cholesterol Education Program [NCEP] definition) with or without diabetes. Demographic and risk factor information was determined for each group, as well as the proportion of each group meeting specific criteria for metabolic syndrome. The prevalence of CHD for each group was then determined. Metabolic syndrome is very common, with ∼44% of the U.S. population over 50 years of age meeting the NCEP criteria. In contrast, diabetes without metabolic syndrome is uncommon (13% of those with diabetes). Older Americans over 50 years of age without metabolic syndrome regardless of diabetes status had the lowest CHD prevalence (8.7% without diabetes, 7.5% with diabetes). Compared with those with metabolic syndrome, people with diabetes without metabolic syndrome did not have an increase in CHD prevalence. Those with metabolic syndrome without diabetes had higher CHD prevalence (13.9%), and those with both metabolic syndrome and diabetes had the highest prevalence of CHD (19.2%) compared with those with neither. Metabolic syndrome was a significant univariate predictor of prevalent CHD (OR 2.07, 95% CI 1.66–2.59). However, blood pressure, HDL cholesterol, and diabetes, but not presence of metabolic syndrome, were significant multivariate predictors of prevalent CHD. The prevalence of CHD markedly increased with the presence of metabolic syndrome. Among people with diabetes, the prevalence of metabolic syndrome was very high, and those with diabetes and metabolic syndrome had the highest prevalence of CHD. Among all individuals with diabetes, prevalence of CHD was increased compared with those with metabolic syndrome without diabetes. However, individuals with diabetes without metabolic syndrome had no greater prevalence of CHD compared with those with neither.

Integrity signals

Registry

Crossref · 10.2337/diabetes.52.5.1210

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Cardiovascular Survey Methods.
Rose, G., & Blackburn, H. (1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-6-1335_2 · Cited by 3,090

Show all 30 references

Sorted by citations

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J. B., Ferrannini, E., & Stern, M. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,400
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
The Metabolic Syndrome
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
“doubling of CVD risk when the MetS is present (377, 390).”
Background
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Metabolic syndrome: definitions and controversies
Kassi, E., Pervanidou, P., Kaltsas, G., & Chrousos, G. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-48 · Cited by 1,565
“Several epidemiological studies have confirmed the increased risk of CVD in individuals with MetS, independently of the diagnostic criteria used [32-39].”
Background
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk
Després, J.-P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Rodés-Cabau, J., Bertrand, O. F., & Poirier, P. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.159228 · Cited by 1,589
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,511
Obesity, Metabolic Syndrome, and Cardiovascular Disease
Grundy, S. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0372 · Cited by 1,395
The Metabolic Syndrome
Grundy, S. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,227
Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
Semenza, G. L. (2013) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104720 · Cited by 1,185
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Mcevoy, J., Meyer, J., Goff, D., Nasrallah, H., Davis, S., Sullivan, L., Meltzer, H., Hsiao, J. K., Stroup, T., & Lieberman, J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,220
American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
The Metabolic Syndrome and 11-Year Risk of Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study
McNeill, A. M., Rosamond, W. D., Girman, C. J., Golden, S. H., Schmidt, M. I., East, H. E., Ballantyne, C. M., & HEISS, G. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.385 · Cited by 1,051
“(26), who reported that although elevated blood pressure, low HDL cholesterol, and diabetes were significantly associated with prevalent CHD, they found no indication of excess risk for the ATP III–defined metabolic syndrome once the individual components had been accounted for in multiplicative risk models.”
Background
Intra-Abdominal Fat Is a Major Determinant of the National Cholesterol Education Program Adult Treatment Panel III Criteria for the Metabolic Syndrome
Carr, D. B., Utzschneider, K. M., Hull, R. L., Kodama, K., Retzlaff, B. M., Brunzell, J. D., Shofer, J. B., Fish, B. E., Knopp, R. H., & Kahn, S. E. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2087 · Cited by 993
Health disparities among lesbian, gay, and bisexual older adults: Results from a population-based study
Fredriksen-Goldsen, K. I., Kim, H.-J., Barkan, S. E., Muraco, A., & Hoy-Ellis, C. P. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301110 · Cited by 965
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial
Orchard, T. J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., Fowler, S., & for the Diabetes Prevention Program Research Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-8-200504190-00009 · Cited by 948
“Although recent studies have provided estimates of the prevalence of the metabolic syndrome in the United States (3, 4), its interrelationship with impaired glucose tolerance is unclear.”
BackgroundInfluentialSelf-citation
Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Scheen, A. J., Finer, N., Hollander, P. A., Jensen, M. D., & Gaal, L. F. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 740
Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds
Grundy, S. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.046 · Cited by 686
National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study
Hunt, K. J., Resendez, R. G., Williams, K., Haffner, S. M., & Stern, M. P. (2004) · Circulation · doi:10.1161/01.cir.0000140762.04598.f9 · Cited by 662
Self-citation
Is visceral obesity the cause of the metabolic syndrome?
Després, J. (2006) · Annals of Medicine · doi:10.1080/07853890500383895 · Cited by 665
Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Metabolic Syndrome: A Clinical and Molecular Perspective
Moller, D. E., & Kaufman, K. D. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104751 · Cited by 636
Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk
Grundy, S. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.080 · Cited by 627
Local Inflammation and Hypoxia Abolish the Protective Anticontractile Properties of Perivascular Fat in Obese Patients
Greenstein, A. S., Khavandi, K., Withers, S., Sonoyama, K., Clancy, O., Jeziorska, M., Laing, I., Yates, A. P., Pemberton, P. W., Malik, R. A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.821181 · Cited by 616
“Incubations performed for arteries with and without PVAT included the following: (1) Adiponectin blocking peptide; (2) single cytokines (TNF, IL-6, or IL-1); (3) TNF and anti-TNF blocking antibody; (4) IL-6 and IL-6 blocking antibody; (5) IL-6 and TNF, followed by incubation with superoxide dismutase and catalase, fol…”
Method
Hypoxia-Inducible Factor 1 and Cardiovascular Disease
Semenza, G. L. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170322 · Cited by 624
The Metabolic Syndrome: Inflammation, Diabetes Mellitus, and Cardiovascular Disease
Haffner, S. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.010 · Cited by 568
Self-citation
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
“National Health and Nutrition Examination Survey III survey and also in individuals with newly diagnosed diabetes (11,12).”
Background
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Girman, C. J., Rhodes, T., Mercuri, M. F., Pyörälà, K., KJEKSHUS, J. K., Pedersen, T. R., Beere, P. A., Gotto, A. M., & Clearfield, M. B. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.09.028 · Cited by 528
A Green Tea Extract High in Catechins Reduces Body Fat and Cardiovascular Risks in Humans
Nagao, T., Hase, T., & Tokimitsu, I. (2007) · Obesity · doi:10.1038/oby.2007.176 · Cited by 524
“A cluster of conditions, such as obesity, hypercholesterolemia, and hypertension, can lead to cardiovascular disease even if they are mild in each case and is known as the metabolic syndrome (13,14).”
Background
AME Position Statement on adrenal incidentaloma
Terzolo, M., Stigliano, A., Chiodini, I., Loli, P., Furlani, L., Arnaldi, G., Reimondo, G., Pia, A., Toscano, V., Zini, M., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1147 · Cited by 523
Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.
Carr, M. C., & Brunzell, J. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0432 · Cited by 493
Insulin resistance and atherosclerosis
Semenkovich, C. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29024 · Cited by 481
Metabolic Syndrome Is Associated with Elevated Oxidative Stress and Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired Antioxidative Activity
Hansel, B., Giral, P., Nobécourt, E., Chantepie, S., Bruckert, É., Chapman, M. J., & Kontush, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0305 · Cited by 476
Metabolic syndrome
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
“…as inflammation, endothelial dysfunction, a prothrombotic state and an excess of circulating small, dense LDL particles as well as abdominal obesity and hepatic steatosis, are not routinely measured in clinical practice, nor are they directly targeted by existing pharmacological therapies 152 .”
Gender differences in the metabolic syndrome and their role for cardiovascular disease
Regitz‐Zagrosek, V., Lehmkuhl, E., & Weickert, M. O. (2006) · Clinical Research in Cardiology · doi:10.1007/s00392-006-0351-5 · Cited by 462
“In Mexican Americans, the NCEP (National Cholesterol Education Program) criteria seemed to be more suitable for identifying individuals with metabolic syndrome or with increased risk of diabetes [4, 5].”
Method
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
Meshkani, R., & Adeli, K. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.018 · Cited by 470
Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians
Fagiolini, A. M., Frank, E., Scott, J., Turkin, S. R., & Kupfer, D. J. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00234.x · Cited by 452
REVIEW: Plasminogen Activator Inhibitor‐1 (PAI‐1): A Key Factor Linking Fibrinolysis and Age‐Related Subclinical and Clinical Conditions
Cesari, M., Pahor, M., & Incalzi, R. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00171.x · Cited by 470
Systolic Blood Pressure in Childhood Predicts Hypertension and Metabolic Syndrome Later in Life
Sun, S. S., Grave, G. D., Siervogel, R. M., Pickoff, A. S., Arslanian, S. A., & Daniels, S. R. (2007) · PEDIATRICS · doi:10.1542/peds.2006-2543 · Cited by 439
Epidemic Obesity and the Metabolic Syndrome
Haffner, S. M., & Taegtmeyer, H. (2003) · Circulation · doi:10.1161/01.cir.0000088845.17586.ec · Cited by 425
Self-citation
Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease
Zivkovic, A. M., German, J. B., & Sanyal, A. J. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.2.285 · Cited by 422
Clinical Importance of Obesity Versus the Metabolic Syndrome in Cardiovascular Risk in Women
Kip, K. E., Marroquin, O. C., Kelley, D. E., Johnson, B. D., Kelsey, S. F., Shaw, L. J., Rogers, W. J., & Reís, S. E. (2004) · Circulation · doi:10.1161/01.cir.0000115514.44135.a8 · Cited by 411
Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385
Thiazolidinediones: the forgotten diabetes medications
Lebovitz, H. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1270-y · Cited by 388
The metabolic syndrome: time for a critical appraisal
Kahn, R., Buse, J. B., Ferrannini, E., & Stern, M. P. (2005) · Diabetologia · doi:10.1007/s00125-005-1876-2 · Cited by 384
The Role of Triglycerides in Atherosclerosis
Talayero, B., & Sacks, F. M. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0220-3 · Cited by 368
“More so, the prevalence of triglyceride (TG) levels above 150 mg/dL is nearly twice as high in subjects with metabolic syndrome [3, 4].”
Background
Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence
Xue, F., & Michels, K. B. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.823s · Cited by 354
Effect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus
Rader, D. J. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.01.003 · Cited by 345
Risk Factors for the Metabolic Syndrome
Carnethon, M. R., Loria, C. M., Hill, J. O., Sidney, S. S., Savage, P. J., & Liu, K. (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2707 · Cited by 343
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus
Ginsberg, H. N., & MacCallum, P. R. (2009) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00044.x · Cited by 331
New aspects in the pathogenesis of diabetic atherothrombosis
Moreno, P., & Fuster, V. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.060 · Cited by 338
Effect of an Intensive Exercise Intervention Strategy on Modifiable Cardiovascular Risk Factors in Subjects With Type 2 Diabetes Mellitus<subtitle>A Randomized Controlled Trial: The Italian Diabetes and Exercise Study (IDES)</subtitle><alt-title>Intensive Exercise and Modifiable CV Risk Factors</alt-title>
Balducci, S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.380 · Cited by 329
Trends in Coronary Heart Disease Epidemiology in India
Gupta, R., Mohan, I., & Narula, J. (2016) · Annals of Global Health · doi:10.1016/j.aogh.2016.04.002 · Cited by 323
Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose
DeFronzo, R. A., & Abdul‐Ghani, M. A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 324
Insulin resistance is a cardiovascular risk factor in humans
Adeva‐Andany, M. M., Martínez‐Rodríguez, J., González-Lucán, M., Fernández‐Fernández, C., & Castro-Quintela, E. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.02.023 · Cited by 322
Nicotinic Acid: Pharmacological Effects and Mechanisms of Action
Gille, A., Bodor, E. T., Ahmed, K., & Offermanns, S. (2007) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094746 · Cited by 316
Perinatal Exposure to Bisphenol A at Reference Dose Predisposes Offspring to Metabolic Syndrome in Adult Rats on a High-Fat Diet
Wei, J., Lin, Y., Li, Y., Ying, C., Chen, J., Song, L., Zhao, Z., Lv, Z., Xia, W., Chen, X., et al. (2011) · Endocrinology · doi:10.1210/en.2011-0045 · Cited by 311
Canadian Cardiovascular Society position statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease
McPherson, R., Frohlich, J. J., Fodor, G. J., & Genest, J. J. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70310-5 · Cited by 306
The metabolic syndrome in children and adolescents
Cruz, M. L., & Goran, M. I. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0012-x · Cited by 302
“G ui de lin es O be si ty [ 44 ] T yp e 2 di ab et es [ 31 ] H yp er te ns io n [1 5] C V D h ea lt h [4 3, 45 ,4 6] P ro po se d gu id el in es”
Coffee and cardiovascular disease: In vitro, cellular, animal, and human studies
BONITA, J., Mandarano, M. A., Shuta, D., & Vinson, J. A. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.01.006 · Cited by 303
Impaired glucose homeostasis and mitochondrial abnormalities in offspring of rats fed a fat-rich diet in pregnancy
Taylor, P. D., McConnell, J., Khan, I. Y., Holemans, K., Lawrence, K. M., Asare-Anane, H., Persaud, S. J., Jones, P. M., Petrie, L., Hanson, M. A., et al. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00355.2004 · Cited by 297
“Metabolic syndrome has reached epidemic proportions amongst Western populations, with an associated increase in childhood type 2 diabetes (2, 4).”
Background
Insulin-like growth factor-1 deficiency and metabolic syndrome
Aguirre, G. A., Ita, J. R. D., de la Garza, R. G., & Castilla‐Cortázar, I. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-015-0762-z · Cited by 297
Diabetes and atherosclerosis: is there a role for hyperglycemia?
Chait, A., & Bornfeldt, K. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800059-jlr200 · Cited by 298
The CardioMetabolic Health Alliance
Sperling, L. S., Mechanick, J. I., Neeland, I. J., Herrick, C. J., Després, J.-P., Ndumele, C. E., Vijayaraghavan, K., Handelsman, Y., Puckrein, G. A., Araneta, M. R. G., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1328 · Cited by 294
Human C-reactive protein and the metabolic syndrome
Devaraj, S., Singh, U. S., & Jialal, I. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832ac03e · Cited by 295
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Chiquette, E., Ramı́rez, G., & DeFronzo, R. A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2097 · Cited by 291
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Grundy, S. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2005 · Cited by 294
n−3 Fatty acids and the metabolic syndrome
Carpentier, Y., Portois, L., & Malaisse, W. J. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1499s · Cited by 286
“As shown by the third National Health and Nutrition Examination Survey, the metabolic syndrome (according to the National Cholesterol Education Program criteria) had a prevalence of 44% among the US population over 50 y of age in 2003 (4); this prevalence is expected to increase in the near future because of the curre…”
Method
Features of the Metabolic Syndrome and Diabetes Mellitus as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis
Katz, R., Wong, N. D., Kronmal, R. A., Takasu, J., Shavelle, D. M., Probstfield, J. L., Bertoni, A. G., Budoff, M. J., & O’Brien, K. D. (2006) · Circulation · doi:10.1161/circulationaha.105.598086 · Cited by 282
“Hispanic 377 (49) 242 (31) 154 (20) 415 (58) 147 (20) 157 (22)”
Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease
Angelico, F., Ben, M. D., Conti, R., Francioso, S., Feole, K., Fiorello, S., Cavallo, M. G., Zalunardo, B., Lirussi, F., Alessandri, C., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1024 · Cited by 286
Abdominal Obesity and the Metabolic Syndrome
Després, J., Lemieux, I., & Alméras, N. (2007) · Springer eBooks · doi:10.1007/978-0-387-32164-6_8 · Cited by 288
“studies have shown that type 2 diabetes is a heterogeneous entity: the more abdominally obese type 2 diabetic patients are, the greater is their likelihood of being characterized by the features of the metabolic syndrome [12] and the higher their corresponding CHD risk will be (Figure 1).”
Background
Dietary patterns, inflammation and the metabolic syndrome.
Ahluwalia, N., Andreeva, V., Kesse-Guyot, E., & Hercberg, S. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.007 · Cited by 259
“[76] Alexander CM, Landsman PB, Teutsch SM, Haffner SM.”
Background
The Metabolic Syndrome and Alzheimer Disease
Razay, G., Vreugdenhil, A., & Wilcock, G. K. (2007) · Archives of Neurology · doi:10.1001/archneur.64.1.93 · Cited by 272
Hypertriglyceridemia
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268
The Rise In Spending Among Medicare Beneficiaries: The Role Of Chronic Disease Prevalence And Changes In Treatment Intensity
Thorpe, K. E., & Howard, D. H. (2006) · Health Affairs · doi:10.1377/hlthaff.25.w378 · Cited by 260
Cardiovascular risk assessment in patients with diabetes
Bertoluci, M. C., & Rocha, V. Z. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0225-1 · Cited by 260
Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study
Mancia, G., Bombelli, M., Corrao, G., Facchetti, R., Madotto, F., Giannattasio, C., Trevano, F. Q., Grassi, G. M., Zanchetti, A., & Sega, R. (2006) · Hypertension · doi:10.1161/01.hyp.0000251933.22091.24 · Cited by 252
Thyroid Hormones and the Metabolic Syndrome
Iwen, K. A., Schröder, E., & Brabant, G. E. (2013) · European Thyroid Journal · doi:10.1159/000351249 · Cited by 257
The Prevalence of Metabolic Syndrome in Various Populations
Kolovou, G. D., Anagnostopoulou, K. K., Salpea, K. D., & Mikhailidis, D. P. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318065c3a1 · Cited by 255
“0% Omani women Meigs, 2003 (73) 24%* In FOS 23% Non-Hispanic whites 21%* Non-Hispanic whites 31% Mexican Americans 30%* Mexican Americans lexander, 2003 (74) 44% USA population 50 years Cook, 2003 (75) 4% Adolescents (USA) 30% Overweight adolescents (USA) Ford, 2003 (76) 25.”
Background
Mortality in schizophrenia.
Auquier, P., Lançon, C., Rouillon, F., Lader, M., & Holmes, C. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1325 · Cited by 249
“The syndrome has been associated with an increased risk for cardiovascular morbidity and mortality.(25,26) Patients with schizophrenia would seem to have a two-fold higher relative risk of developing coronary heart disease (CHD) compared with the general population.”
Background
CD36 Deficiency Rescues Lipotoxic Cardiomyopathy
Yang, J., Sambandam, N., Han, X., Gross, R. W., Courtois, M., Kovacs, A., Febbraio, M., Finck, B. N., & Kelly, D. P. (2007) · Circulation Research · doi:10.1161/01.res.0000264104.25265.b6 · Cited by 246
“Lipotoxic cardiomyopathy has been described in animal models of obesity and diabetes.15,16 In addition, humans with inborn errors in mitochondrial FA oxidation also develop cardiomyopathy associated with myocyte lipid accumulation.42 Proposed mechanisms for the development of cardiac dysfunction secondary to myocyte l…”
Background
Metabolic Syndrome Modifies the Cardiovascular Risk Associated With Angiographic Coronary Artery Disease in Women: A Report From the Women’s Ischemia Syndrome Evaluation
Marroquin, O. C., Kip, K. E., Kelley, D. E., Johnson, B. D., Shaw, L. J., Bairey Merz, C. N., Sharaf, B. L., Pepine, C. J., Sopko, G., & Reis, S. E. (2004) · Circulation · doi:10.1161/01.cir.0000115517.26897.a7 · Cited by 243
“†Women without treated diabetes yet with at least 3 of the 5 following factors present: (1) waist circumference 88 cm; (2) triglycerides150 mg/dL; (3) HDL 50 mg/dL; (4) systolic BP 130 mm Hg or diastolic BP 85 mm Hg or recent use of antihypertensive agents; ( 5 ) fasting glucose 110 mg/dL.”
BackgroundMethod
Asian Americans Have Greater Prevalence of Metabolic Syndrome Despite Lower Body Mass Index
Palaniappan, L., Wong, E. C., Shin, J. J., Fortmann, S., & Lauderdale, D. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.152 · Cited by 236
Metabolic syndrome: recent prevalence in East and Southeast Asian populations.
Nestel, P. J., Lyu, R., Low, L. P., Sheu, W. H., Nitiyanant, W., Saito, I., & Tan, C. E. (2007) · PubMed · Cited by 236
Insulin resistance and the endothelium
Hsueh, W. A., Lyon, C. J., & Quiñones, M. J. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.042 · Cited by 236
Hypoxia-Inducible Factor as an Angiogenic Master Switch
Hashimoto, T., & Shibasaki, F. (2015) · Frontiers in Pediatrics · doi:10.3389/fped.2015.00033 · Cited by 242
Gender Aspects of the Role of the Metabolic Syndrome as a Risk Factor for Cardiovascular Disease
Regitz‐Zagrosek, V., Lehmkuhl, E., & Mahmoodzadeh, S. (2007) · Gender Medicine · doi:10.1016/s1550-8579(07)80056-8 · Cited by 229
Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword
Qi, X.-Y., Qu, S.-L., Xiong, W., Rom, O., Chang, L., & Jiang, Z. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0777-x · Cited by 239
Defective Mitochondrial Biogenesis
Nisoli, E., Clementi, E., Carruba, M. O., & Moncada, S. (2007) · Circulation Research · doi:10.1161/01.res.0000259591.97107.6c · Cited by 229
Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases
Corona, G., Mannucci, E., Forti, G., & Maggi, M. (2009) · International Journal of Andrology · doi:10.1111/j.1365-2605.2008.00951.x · Cited by 223
Metabolic Syndrome as a Predictor of All-Cause and Cardiovascular Mortality in Type 2 Diabetes
Bruno, G., Merletti, F., Biggeri, A., Bargero, G., Ferrero, S., Runzo, C., Cerai, S. P., Pagano, G., & Cavallo‐Perin, P. (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2689 · Cited by 224
“The prevalence of CHD in diabetic subjects of the National Health and Nutrition Examination Survey (NHANES) III Study increases with the number of the components of the metabolic syndrome (NCEP-III criteria) (6).”
Background
Obesity-Related Metabolic Syndrome: Mechanisms of Sympathetic Overactivity
Canale, M. P., di Villahermosa, S. M., Martino, G., Rovella, V., Noce, A., LORENZO, A. D., & Daniele, N. D. (2013) · International Journal of Endocrinology · doi:10.1155/2013/865965 · Cited by 224
“The MetS central feature is obesity, and the MetS is a growing epidemic in the United States and throughout the world [4, 5].”
Background
Management of cardiovascular diseases in patients with obesity
Lavie, C. J., Arena, R., Alpert, M. A., Milani, R. V., & Ventura, H. O. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.108 · Cited by 218
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 235
Sympathetic Neural Activation in Nondiabetic Metabolic Syndrome and Its Further Augmentation by Hypertension
Huggett, R. J., Burns, J., Mackintosh, A. F., & Mary, D. A. S. G. (2004) · Hypertension · doi:10.1161/01.hyp.0000147893.08533.d8 · Cited by 211
Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm
Gorter, P. M., Olijhoek, J. K., van der Graaf, Y., Algra, A., Rabelink, T. J., & Visseren, F. L. J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.12.033 · Cited by 216
Aerobic, resistance or combined training: a systematic review and meta-analysis of exercise to reduce cardiovascular risk in adults with metabolic syndrome
Wewege, M. A., Thom, J. M., Rye, K.-A., & Parmenter, B. J. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.002 · Cited by 210

Authors: Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M.
Affiliations: Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
The University of Texas at San Antonio Health Science Center (US)
ORCID: Alexander, Charles M.
Teutsch, Steven M.
Venue: Diabetes
Publisher: American Diabetes Association
Published: 2003-05-01
Volume: 52
Issue: 5
Pages: 1210-1214
ISSN: 0012-1797 (ISSN-L)
1939-327X
DOI: 10.2337/diabetes.52.5.1210
OpenAlex: W2151152924
Cited by: 1,475
References: 30
Citations by year: 2026: 9 · 2025: 14 · 2024: 18 · 2023: 20 · 2022: 30 · 2021: 37 · 2020: 32 · 2019: 30 · 2018: 42 · 2017: 39 · 2016: 51 · 2015: 43 · 2014: 61 · 2013: 65 · 2012: 73
FWCI: 77.32
Type: journal article
Language: en
Open access: closed
Locations: Diabetes (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: metabolic syndrome, coronary artery disease, prevalence, older adults, NCEP criteria, NHANES III, cardiovascular risk factors, blood pressure, HDL cholesterol
MeSH terms: Age Factors, Blood Pressure, Body Constitution, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Patient Education as Topic, Physical Examination, Surveys and Questionnaires, Risk Factors, Smoking, United States, Prevalence, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks